Preempt future health risks.

Airfinity provides global health intelligence and analytics that decision makers can trust, understand and act upon to save lives.

The world’s most trusted independent health intelligence, cited over 16,000 times in 2022


Analysis & Insights

Breakthrough Treatments Could Relegate RSV Seasons Like 2023 To History Books
Breakthrough Treatments Could Relegate RSV Seasons Like 2023 To History Books

In his latest op-ed for PharmaBoardroom, Dr Matt Linley, Airfinity's Senior Director for Analytics and Forecasting looks at the industry-defining breakthroughs expected in 2023 in the RSV market.

Read More →

More from Airfinity
Airfinity launches new platform IDA 360 to track all infectious disease vaccine and treatment candidatesFormer Editor of The Economist joins Airfinity as advisor China to see one longer, more severe COVID wave as Lunar Festival fuels outbreakAirfinity hosting industry leader roundtable on the future of the RSV marketChina’s COVID-19 wave forecast to have two peaks where cases could reach 4.2 million a dayAirfinity launches intelligence tool to drive innovation in AMR researchIntroducing Airfinity Biorisk: Risk Surveillance and Analytics for 160+ Infectious DiseasesView All →
In the News
Covid Boosters Sour for Pfizer, Moderna With Uptake Rate at 16%

Bloomberg | Mar 10, 2023

U.S. to lift covid testing requirements on travelers from China

The Washington Post | Mar 7, 2023

Breakthrough Treatments Could Relegate RSV Seasons Like 2023 To History Books

PharmaBoardroom | Feb 15, 2023

No new variants emerged from China’s Covid outbreak, study finds

NBC News | Feb 8, 2023

View All →

A pioneer in predictive health intelligence


What's happening in a given disease area?

Airfinity is the most comprehensive, single source of intelligence for new developments in your chosen area.


Identify the true need for a vaccine or a treatment.

Our suite of dynamic predictive indicators help you navigate highly dynamic and uncertain market developments and see the real opportunities.


Maximise impact to save lives

Our analytics and probabilistic tools inform key decisions on resource allocation, investment and procurement decisions to maximise impact of a given drug or vaccine and ultimately improve as many lives as possible.

The world's most comprehensive infectious disease solutions.

Airfinity combines proprietary surveillance tools and forecast models with expert analysis for dozens of infectious diseases, including COVID-19, Monkeypox, Influenza and RSV.


New science

Market & Production


Disease & Prevalence

Learn More →

What our users say?


“The Airfinity report is a guide for world leaders to fix a more ambitious action plan.”

Gordon Brown, WHO Ambassador for Global Health Financing & former UK Prime Minister

hm government

“Airfinity has been instrumental in our country's COVID response.”

Head of UK Government
Vaccine Task Force


“Vaccine production data from Airfinity has been spot on. In a fast moving pandemic, these forecasts are really important for evidence-based policy making.”

Director General,

the economist

“Airfinity has been critical in furnishing us and the rest of the world with COVID-19 numbers.”

James Fransham, Data Journalist,
The Economist